These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38717560)

  • 1. Pathogenic MTOR somatic variant causing focal cortical dysplasia drives hyperexcitability via overactivation of neuronal GluN2C N-methyl-D-aspartate receptors.
    Pineau L; Buhler E; Tarhini S; Bauer S; Crepel V; Watrin F; Cardoso C; Represa A; Szepetowski P; Burnashev N
    Epilepsia; 2024 Jul; 65(7):2111-2126. PubMed ID: 38717560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. mTOR Hyperactivity Levels Influence the Severity of Epilepsy and Associated Neuropathology in an Experimental Model of Tuberous Sclerosis Complex and Focal Cortical Dysplasia.
    Nguyen LH; Mahadeo T; Bordey A
    J Neurosci; 2019 Apr; 39(14):2762-2773. PubMed ID: 30700531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective suppression of excessive GluN2C expression rescues early epilepsy in a tuberous sclerosis murine model.
    Lozovaya N; Gataullina S; Tsintsadze T; Tsintsadze V; Pallesi-Pocachard E; Minlebaev M; Goriounova NA; Buhler E; Watrin F; Shityakov S; Becker AJ; Bordey A; Milh M; Scavarda D; Bulteau C; Dorfmuller G; Delalande O; Represa A; Cardoso C; Dulac O; Ben-Ari Y; Burnashev N
    Nat Commun; 2014 Aug; 5():4563. PubMed ID: 25081057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Somatic double-hit in MTOR and RPS6 in hemimegalencephaly with intractable epilepsy.
    Pelorosso C; Watrin F; Conti V; Buhler E; Gelot A; Yang X; Mei D; McEvoy-Venneri J; Manent JB; Cetica V; Ball LL; Buccoliero AM; Vinck A; Barba C; Gleeson JG; Guerrini R; Represa A
    Hum Mol Genet; 2019 Nov; 28(22):3755-3765. PubMed ID: 31411685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brain somatic mutations in MTOR cause focal cortical dysplasia type II leading to intractable epilepsy.
    Lim JS; Kim WI; Kang HC; Kim SH; Park AH; Park EK; Cho YW; Kim S; Kim HM; Kim JA; Kim J; Rhee H; Kang SG; Kim HD; Kim D; Kim DS; Lee JH
    Nat Med; 2015 Apr; 21(4):395-400. PubMed ID: 25799227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cortical Dysplasia and the mTOR Pathway: How the Study of Human Brain Tissue Has Led to Insights into Epileptogenesis.
    Lee WS; Baldassari S; Stephenson SEM; Lockhart PJ; Baulac S; Leventer RJ
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GABAergic Interneuron and Neurotransmission Are mTOR-Dependently Disturbed in Experimental Focal Cortical Dysplasia.
    Zhong S; Zhao Z; Xie W; Cai Y; Zhang Y; Ding J; Wang X
    Mol Neurobiol; 2021 Jan; 58(1):156-169. PubMed ID: 32909150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Somatic Mutations in TSC1 and TSC2 Cause Focal Cortical Dysplasia.
    Lim JS; Gopalappa R; Kim SH; Ramakrishna S; Lee M; Kim WI; Kim J; Park SM; Lee J; Oh JH; Kim HD; Park CH; Lee JS; Kim S; Kim DS; Han JM; Kang HC; Kim HH; Lee JH
    Am J Hum Genet; 2017 Mar; 100(3):454-472. PubMed ID: 28215400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brain somatic mutations in MTOR leading to focal cortical dysplasia.
    Lim JS; Lee JH
    BMB Rep; 2016 Feb; 49(2):71-2. PubMed ID: 26779999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of MTOR Mutations With Developmental Brain Disorders, Including Megalencephaly, Focal Cortical Dysplasia, and Pigmentary Mosaicism.
    Mirzaa GM; Campbell CD; Solovieff N; Goold C; Jansen LA; Menon S; Timms AE; Conti V; Biag JD; Adams C; Boyle EA; Collins S; Ishak G; Poliachik S; Girisha KM; Yeung KS; Chung BHY; Rahikkala E; Gunter SA; McDaniel SS; Macmurdo CF; Bernstein JA; Martin B; Leary R; Mahan S; Liu S; Weaver M; Doerschner M; Jhangiani S; Muzny DM; Boerwinkle E; Gibbs RA; Lupski JR; Shendure J; Saneto RP; Novotny EJ; Wilson CJ; Sellers WR; Morrissey M; Hevner RF; Ojemann JG; Guerrini R; Murphy LO; Winckler W; Dobyns WB
    JAMA Neurol; 2016 Jul; 73(7):836-845. PubMed ID: 27159400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. mTOR pathway activation in focal cortical dysplasia.
    Kumari K; Sharma MC; Kakkar A; Malgulwar PB; Pathak P; Suri V; Sarkar C; Chandra SP; Faruq M
    Ann Diagn Pathol; 2020 Jun; 46():151523. PubMed ID: 32325422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered inhibition in tuberous sclerosis and type IIb cortical dysplasia.
    Talos DM; Sun H; Kosaras B; Joseph A; Folkerth RD; Poduri A; Madsen JR; Black PM; Jensen FE
    Ann Neurol; 2012 Apr; 71(4):539-51. PubMed ID: 22447678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Somatic Mutations Activating the mTOR Pathway in Dorsal Telencephalic Progenitors Cause a Continuum of Cortical Dysplasias.
    D'Gama AM; Woodworth MB; Hossain AA; Bizzotto S; Hatem NE; LaCoursiere CM; Najm I; Ying Z; Yang E; Barkovich AJ; Kwiatkowski DJ; Vinters HV; Madsen JR; Mathern GW; Blümcke I; Poduri A; Walsh CA
    Cell Rep; 2017 Dec; 21(13):3754-3766. PubMed ID: 29281825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Focal cortical dysplasia II caused by brain somatic mutation of IRS-1 is associated with ERK signaling pathway activation.
    Li X; Wang T; Liu N; Cai A; Zhang J; Zhang F; Liu Q; Wang J; Wu Y; Gao K; Jiang YW
    Cereb Cortex; 2024 Jun; 34(6):. PubMed ID: 38836287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Somatic variants in diverse genes leads to a spectrum of focal cortical malformations.
    Lai D; Gade M; Yang E; Koh HY; Lu J; Walley NM; Buckley AF; Sands TT; Akman CI; Mikati MA; McKhann GM; Goldman JE; Canoll P; Alexander AL; Park KL; Von Allmen GK; Rodziyevska O; Bhattacharjee MB; Lidov HGW; Vogel H; Grant GA; Porter BE; Poduri AH; Crino PB; Heinzen EL
    Brain; 2022 Aug; 145(8):2704-2720. PubMed ID: 35441233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New insights into a spectrum of developmental malformations related to mTOR dysregulations: challenges and perspectives.
    Mühlebner A; Bongaarts A; Sarnat HB; Scholl T; Aronica E
    J Anat; 2019 Sep; 235(3):521-542. PubMed ID: 30901081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spatial omics reveals molecular changes in focal cortical dysplasia type II.
    Vermeulen I; Rodriguez-Alvarez N; François L; Viot D; Poosti F; Aronica E; Dedeurwaerdere S; Barton P; Cillero-Pastor B; Heeren RMA
    Neurobiol Dis; 2024 Jun; 195():106491. PubMed ID: 38575092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NPRL3 loss alters neuronal morphology, mTOR localization, cortical lamination and seizure threshold.
    Iffland PH; Everett ME; Cobb-Pitstick KM; Bowser LE; Barnes AE; Babus JK; Romanowski AJ; Baybis M; Elziny S; Puffenberger EG; Gonzaga-Jauregui C; Poulopoulos A; Carson VJ; Crino PB
    Brain; 2022 Nov; 145(11):3872-3885. PubMed ID: 35136953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Balloon cells promote immune system activation in focal cortical dysplasia type 2b.
    Zimmer TS; Broekaart DWM; Luinenburg M; Mijnsbergen C; Anink JJ; Sim NS; Michailidou I; Jansen FE; van Rijen PC; Lee JH; François L; van Eyll J; Dedeurwaerdere S; van Vliet EA; Mühlebner A; Mills JD; Aronica E
    Neuropathol Appl Neurobiol; 2021 Oct; 47(6):826-839. PubMed ID: 34003514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of extracellular regulated kinase and mechanistic target of rapamycin pathway in focal cortical dysplasia.
    Patil VV; Guzman M; Carter AN; Rathore G; Yoshor D; Curry D; Wilfong A; Agadi S; Swann JW; Adesina AM; Bhattacharjee MB; Anderson AE
    Neuropathology; 2016 Apr; 36(2):146-56. PubMed ID: 26381727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.